Announcing a $65 million Series F financing round, MicroTransponder, Inc., one of the fastest-growing stroke companies, is transforming the stroke continuum of care with its FDA-approved Vivistim Paired VNS System. The round was led by US Venture Partners (USVP) and the syndicate of current investors, Osage University Partners, Action Potential Venture Capital, GPG Ventures, The Vertical Group and Exceller Hunt Ventures, as well as two new investors, Gilde Healthcare and Longitude Capital.